PMID- 29067438
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20181202
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 16
IP  - 2
DP  - 2017 Aug
TI  - miRNA-140 inhibits C3H10T1/2 mesenchymal stem cell proliferation by targeting 
      CXCL12 during transforming growth factor-beta3-induced chondrogenic differentiation.
PG  - 1389-1394
LID - 10.3892/mmr.2017.6720 [doi]
AB  - The aim of the present study was to investigate the role of microRNA (miRNA or 
      miR)-140 in C3H10T1/2 mesenchymal stem cells (MSCs). Cluster analysis was used to 
      evaluate the miRNA expression profile. The expression level of miRNA‑140 was 
      validated by reverse transcription‑quantitative polymerase chain reaction 
      (RT‑qPCR). TargetScan and microRNA.org databases were used to predict target 
      miRNAs and cartilage‑associated target genes. Binding sites between miR‑140 and 
      the target gene were predicted by bioinformatics software. A dual‑luciferase 
      reporter assay was performed to determine whether miR‑140 could target C‑X‑C 
      motif chemokine ligand 12 (CXCL12). Following the promotion/inhibition of 
      miR‑140, 1, 7 and 14 days following transforming growth factor‑beta3 
      (TGF‑beta3)‑induction, western blotting was utilized to evaluate CXCL12 protein 
      levels. MTT assays and alcian blue staining were applied to assess C3H10T1/2 MSC 
      viability and chondrogenic differentiation, respectively. In the TGF‑beta3‑induced 
      group, RT‑qPCR verified that the mRNA level of Mus musculus (mmu)‑miR‑140 was 
      significantly elevated when compared with the control group. miR‑140 was 
      predicted to recognize and interact with CXCL12‑3'UTR and the dual luciferase 
      reporter assay further validated that miR‑140 targeted the predicted region of 
      CXCL12. CXCL12 was markedly decreased following miR‑140 overexpression and 
      visibly increased following miR‑140 inhibition. In addition, the level of CXCL12 
      expression declined as the duration of induction increased. Following the 
      promotion/inhibition of miR‑140, at 1 and 7 days following TGF‑beta3‑induction, 
      C3H10T1/2 MSCs inhibited or promoted cell viability, respectively, when compared 
      with the control groups. In addition, in pellets achieved by chondrogenic 
      differentiation following the induction of C3H10T1/2 MSCs for 7 days, alcian blue 
      staining revealed no significant difference in characteristic extracellular 
      matrix glycosaminoglycans between the miR‑140 up and downregulated groups, and 
      their respective control groups. The present study concludes that miRNA‑140 
      inhibition promoted C3H10T1/2 MSC viability however, not C3H10T1/2 MSC 
      differentiation by targeting and reducing CXCL12 protein levels during the 
      process of TGF‑beta3‑induced chondrogenic differentiation. In conclusion, the 
      present study provided a potential target for the treatment of cartilage 
      defection.
FAU - Wa, Qingde
AU  - Wa Q
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Zunyi Medical 
      College, Zunyi, Guizhou 563003, P.R. China.
FAU - Liu, Yi
AU  - Liu Y
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Zunyi Medical 
      College, Zunyi, Guizhou 563003, P.R. China.
FAU - Huang, Shuai
AU  - Huang S
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Sun Yat‑sen 
      University, Guangzhou, Guangdong 510080, P.R. China.
FAU - He, Peiheng
AU  - He P
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Sun Yat‑sen 
      University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Zuo, Jianwei
AU  - Zuo J
AD  - Department of Sports Medicine, Shenzhen Hospital of Peking University, Shenzhen, 
      Guangdong 518036, P.R. China.
FAU - Li, Xing
AU  - Li X
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Sun Yat‑sen 
      University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Li, Ziqing
AU  - Li Z
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Sun Yat‑sen 
      University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Dong, Liming
AU  - Dong L
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Zunyi Medical 
      College, Zunyi, Guizhou 563003, P.R. China.
FAU - Peng, Jiachen
AU  - Peng J
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Zunyi Medical 
      College, Zunyi, Guizhou 563003, P.R. China.
FAU - Wu, Shuhong
AU  - Wu S
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Zunyi Medical 
      College, Zunyi, Guizhou 563003, P.R. China.
FAU - Chen, Fang
AU  - Chen F
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Zunyi Medical 
      College, Zunyi, Guizhou 563003, P.R. China.
FAU - Cai, Dongfeng
AU  - Cai D
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Zunyi Medical 
      College, Zunyi, Guizhou 563003, P.R. China.
FAU - Zou, Xuenong
AU  - Zou X
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Sun Yat‑sen 
      University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Liao, Wenbo
AU  - Liao W
AD  - Department of Orthopedic Surgery, The First Affiliated Hospital of Zunyi Medical 
      College, Zunyi, Guizhou 563003, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170608
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (3' Untranslated Regions)
RN  - 0 (Antagomirs)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (MIRN140 microRNA, mouse)
RN  - 0 (MicroRNAs)
RN  - 0 (Transforming Growth Factor beta3)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Animals
MH  - Antagomirs/metabolism
MH  - Base Sequence
MH  - Binding Sites
MH  - Cell Differentiation/drug effects
MH  - Cell Line
MH  - Cell Proliferation
MH  - Cell Survival/drug effects
MH  - Chemokine CXCL12/chemistry/genetics/*metabolism
MH  - Chondrogenesis/*drug effects
MH  - Mesenchymal Stem Cells/cytology
MH  - Mice
MH  - MicroRNAs/antagonists & inhibitors/genetics/*metabolism
MH  - Mutagenesis, Site-Directed
MH  - Sequence Alignment
MH  - Transforming Growth Factor beta3/*pharmacology
MH  - Up-Regulation/drug effects
EDAT- 2017/10/27 06:00
MHDA- 2018/06/12 06:00
CRDT- 2017/10/26 06:00
PHST- 2016/03/07 00:00 [received]
PHST- 2017/03/10 00:00 [accepted]
PHST- 2017/10/27 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
PHST- 2017/10/26 06:00 [entrez]
AID - 10.3892/mmr.2017.6720 [doi]
PST - ppublish
SO  - Mol Med Rep. 2017 Aug;16(2):1389-1394. doi: 10.3892/mmr.2017.6720. Epub 2017 Jun 
      8.